BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review. Drug Metab Dispos. 2014;42:1991-2001. [PMID: 25271211 DOI: 10.1124/dmd.114.060392] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Yu J, Zhou Z, Tay-sontheimer J, Levy RH, Ragueneau-majlessi I. Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings. Journal of Pharmaceutical Sciences 2017;106:2312-25. [DOI: 10.1016/j.xphs.2017.04.004] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 11.6] [Reference Citation Analysis]
2 Yu J, Zhou Z, Owens KH, Ritchie TK, Ragueneau-majlessi I. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015. Drug Metab Dispos 2016;45:86-108. [DOI: 10.1124/dmd.116.073411] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
3 Geist MJP, Siller N, Egerer G, Bardenheuer H, Burhenne J, Mikus G. Decreased Cytochrome P450 3A activity in palliative patients with haematological diseases: Potential impact on supportive drug therapies. Basic Clin Pharmacol Toxicol 2019. [DOI: 10.1111/bcpt.13232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Stevens LJ, Donkers JM, Dubbeld J, Vaes WHJ, Knibbe CAJ, Alwayn IPJ, van de Steeg E. Towards human ex vivo organ perfusion models to elucidate drug pharmacokinetics in health and disease. Drug Metabolism Reviews 2020;52:438-54. [DOI: 10.1080/03602532.2020.1772280] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Aronson JK. Toward standardized reporting of drug interactions: the READI checklist for anecdotal reports. Expert Rev Clin Pharmacol 2015;8:399-409. [PMID: 26018632 DOI: 10.1586/17512433.2015.1049598] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 . Phase 1-Phase 3 Clinical Studies, Procedures, Responsibilities, and Documentation. Translational ADMET for Drug Therapy. Hoboken: John Wiley & Sons, Inc; 2015. pp. 277-306. [DOI: 10.1002/9781118838440.ch10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Kovacsics D, Patik I, Özvegy-Laczka C. The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions. Expert Opin Drug Metab Toxicol 2017;13:409-24. [PMID: 27783531 DOI: 10.1080/17425255.2017.1253679] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
8 Palatini P, De Martin S. Pharmacokinetic drug interactions in liver disease: An update. World J Gastroenterol 2016; 22(3): 1260-1278 [PMID: 26811663 DOI: 10.3748/wjg.v22.i3.1260] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
9 Gao S, Zhou X, Lang L, Liu H, Li J, Li H, Wei S, Wang D, Xu Z, Cai H, Zhao Y, Zou W. Simultaneous Determination of Schisandrin and Promethazine with Its Metabolite in Rat Plasma by HPLC-MS/MS and Its Application to a Pharmacokinetic Study. Int J Anal Chem 2019;2019:3497045. [PMID: 31885590 DOI: 10.1155/2019/3497045] [Reference Citation Analysis]
10 Ramsden D, Fung C, Hariparsad N, Kenny JR, Mohutsky M, Parrott NJ, Robertson S, Tweedie DJ. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates. Drug Metab Dispos 2019;47:1206-21. [PMID: 31439574 DOI: 10.1124/dmd.119.087270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Hua L, Chiang CW, Cong W, Li J, Wang X, Cheng L, Feng W, Quinney SK, Wang L, Li L. The Cancer Drug Fraction of Metabolism Database. CPT Pharmacometrics Syst Pharmacol 2019;8:511-9. [PMID: 31206254 DOI: 10.1002/psp4.12417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
12 Bohnert T, Patel A, Templeton I, Chen Y, Lu C, Lai G, Leung L, Tse S, Einolf HJ, Wang YH, Sinz M, Stearns R, Walsky R, Geng W, Sudsakorn S, Moore D, He L, Wahlstrom J, Keirns J, Narayanan R, Lang D, Yang X; International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Victim Drug-Drug Interactions Working Group. Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective. Drug Metab Dispos 2016;44:1399-423. [PMID: 27052879 DOI: 10.1124/dmd.115.069096] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
13 Hakkola J, Hukkanen J, Turpeinen M, Pelkonen O. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol 2020;94:3671-722. [PMID: 33111191 DOI: 10.1007/s00204-020-02936-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
14 Lüpfert C, Dyroff M, von Richter O, Gallemann D, El Bawab S, Dolgos H, Jung D, Hecht S, Johne A. A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide. CPT Pharmacometrics Syst Pharmacol 2018;7:829-37. [PMID: 30311747 DOI: 10.1002/psp4.12360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Saravanakumar A, Sadighi A, Ryu R, Akhlaghi F. Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016. Clin Pharmacokinet 2019;58:1281-94. [PMID: 30972694 DOI: 10.1007/s40262-019-00750-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
16 Liu J, Liu H, Zeng Q. The effect of naringenin on the pharmacokinetics of ibrutinib in rat: A drug–drug interaction study. Biomedical Chromatography 2019;33:e4507. [DOI: 10.1002/bmc.4507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
17 Krämer SD, Aschmann HE, Hatibovic M, Hermann KF, Neuhaus CS, Brunner C, Belli S. When barriers ignore the "rule-of-five". Adv Drug Deliv Rev 2016;101:62-74. [PMID: 26877103 DOI: 10.1016/j.addr.2016.02.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
18 Russo NW, Petrucci G, Rocca B. Aspirin, stroke and drug-drug interactions. Vascular Pharmacology 2016;87:14-22. [DOI: 10.1016/j.vph.2016.10.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
19 Yu J, Petrie ID, Levy RH, Ragueneau-Majlessi I. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos 2019;47:135-44. [PMID: 30442649 DOI: 10.1124/dmd.118.084905] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
20 Geist MJP, Ziesenitz VC, Bardenheuer HJ, Burhenne J, Skopp G, Mikus G. Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients. Sci Rep 2019;9:14635. [PMID: 31601999 DOI: 10.1038/s41598-019-51279-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. Drug Metab Dispos 2018;46:835-45. [PMID: 29572333 DOI: 10.1124/dmd.117.078691] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 12.8] [Reference Citation Analysis]
22 Vimercati S, Büchi M, Zielinski J, Peduto N, Mevissen M. Testosterone metabolism of equine single CYPs of the 3A subfamily compared to the human CYP3A4. Toxicology in Vitro 2017;41:83-91. [DOI: 10.1016/j.tiv.2017.02.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 MacBrayne CE, Castillo-Mancilla J, Burton JR Jr, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother 2018;73:156-9. [PMID: 29029135 DOI: 10.1093/jac/dkx344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Yu J, Wang Y, Ragueneau-Majlessi I. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations. Drug Metab Dispos 2022;50:1-7. [PMID: 34620694 DOI: 10.1124/dmd.121.000401] [Reference Citation Analysis]
25 Feltrin C, Farias IV, Sandjo LP, Reginatto FH, Simões CMO. Effects of Standardized Medicinal Plant Extracts on Drug Metabolism Mediated by CYP3A4 and CYP2D6 Enzymes. Chem Res Toxicol 2020;33:2408-19. [DOI: 10.1021/acs.chemrestox.0c00182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fan Y, Sun B, Agarwal S, Zhang L. Review of Transporter-Related Postmarketing Requirement or Postmarketing Commitment Studies. The Journal of Clinical Pharmacology 2016;56:S193-204. [DOI: 10.1002/jcph.770] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Fowler S, Morcos PN, Cleary Y, Martin-Facklam M, Parrott N, Gertz M, Yu L. Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities. Curr Pharmacol Rep 2017;3:36-49. [PMID: 28261547 DOI: 10.1007/s40495-017-0082-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
28 Ellens H, Meng Z, Le Marchand SJ, Bentz J. Mechanistic kinetic modeling generates system-independent P-glycoprotein mediated transport elementary rate constants for inhibition and, in combination with 3D SIM microscopy, elucidates the importance of microvilli morphology on P-glycoprotein mediated efflux activity. Expert Opin Drug Metab Toxicol 2018;14:571-84. [PMID: 29788828 DOI: 10.1080/17425255.2018.1480720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Lee S, Arya V, Yang X, Volpe DA, Zhang L. Evaluation of transporters in drug development: Current status and contemporary issues. Advanced Drug Delivery Reviews 2017;116:100-18. [DOI: 10.1016/j.addr.2017.07.020] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
30 Xue Y, Hoffmann M, Tong Z, Wu X(, Vallejo M, Melo B, Ye Y, Thomas M, Liu Y, Weiss D, Surapaneni S. Use of 4β-hydroxycholesterol in animal and human plasma samples as a biomarker for CYP3A induction. Bioanalysis 2016;8:215-28. [DOI: 10.4155/bio.15.241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Iwatsubo T. Evaluation of drug-drug interactions in drug metabolism: Differences and harmonization in guidance/guidelines. Drug Metab Pharmacokinet 2020;35:71-5. [PMID: 31757749 DOI: 10.1016/j.dmpk.2019.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
32 Santos CBR, Santos KLB, Cruz JN, Leite FHA, Borges RS, Taft CA, Campos JM, Silva CHTP. Molecular modeling approaches of selective adenosine receptor type 2A agonists as potential anti-inflammatory drugs. J Biomol Struct Dyn 2021;39:3115-27. [PMID: 32338151 DOI: 10.1080/07391102.2020.1761878] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]